Recorded Presentation from the 2015 NCCN Immuno-oncology Webinar Series for Pharmacists - Identification and Management of Toxicities with Immuno-oncologic Therapy
The 2015 NCCN Immuno-oncology Webinar Series for Pharmacists consists of three webinars that examine the immune system, how immune modulation works and its relevance in treating cancer, dosage and administration preparations of immunotherapeutic options, and safety and efficacy issues related to immunotherapy.
This educational program is designed to meet the educational needs of clinical oncology pharmacists and pharmacy directors who manage patients on cancer immunotherapy.
Following this activity, participants should be able to:
- Compare and contrast toxicity profiles of immunotherapy and their management
- Outline management recommendations for common toxicities
- Formulate patient education strategies to increase patient compliance/adherence and improve quality of care
Vananh Trinh, PharmD, BCOP
The University of Texas MD Anderson Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have no financial relationships to disclose:
VanAnh Trinh, PharmD, BCOP
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser
The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Lauren Gallagher, RPh, PhD; Kristina M. Gregory, RN, MSN, OCN; Evelyn Handel, PharmD, BCPS, BCOP; Rashmi Kumar, PhD; Sarika M. Trikha, PharmD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-15-150-H05-P
Release date: December 23, 2015
Expiration date: December 23, 2016
- 0.75 ACPE contact hours
- 0.75 Participation